arrow
J

Janet B. McGill

Washington University School of Medicine
H指数:85
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Front Cover

封面

2026-09-300
OAAI
Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE

在FINE-ONE研究的预设分析中考察非奈利酮引起的急性eGFR变化

2026-09-160
OAAI
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial

同时起始非奈利酮和恩帕格利福辛对白蛋白尿的影响:一项随机CONFIDENCE试验的参与者水平探索性分析,不考虑基线HbA1c水平

2026-08-050
OAAI
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of CONFIDENCE Randomized Trial

使用恩格列净、非格列美酮或两者时的血钾过高风险:CONFIDENCE随机试验的二次分析

JACC
IF0
2025-11-070
OAAI
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both Post Hoc Analyses of CONFIDENCE Trial

基线肾功能、白蛋白尿及尿白蛋白-肌酐比值降低:与Finnerenone、Empagliflozin或两者联合治疗的CONFIDENCE试验事后分析

2025-11-010
PRE
Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations

比较CKD、T1D和T2D人群:基于FINE-ONE和FIDELITY人群的视角

2025-10-010
OAAI
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia. Pre-Specified Analysis of CONFIDENCE

同时启动非奈利酮和恩帕吉洛芬对亚洲人群尿白蛋白肌酐比值的影响:CONFIDENCE研究的预先指定分析

2025-09-012
OA
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial

CONFIDENCE试验中,在不同肾脏风险谱中同时启动finerenone和empagliflozin的治疗。

2025-08-010
OAAI